
First published in the *Government Gazette*, Electronic Edition, on 7 September 2021 at 9 pm.

No. S 682

INFECTIOUS DISEASES ACT
(CHAPTER 137)

INFECTIOUS DISEASES
(MASS GATHERING TESTING FOR
CORONAVIRUS DISEASE 2019)
(AMENDMENT NO. 9) REGULATIONS 2021

In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 9) Regulations 2021 and come into operation on 8 September 2021.

Amendment of regulation 8A

2. Regulation 8A(4) of the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) Regulations 2021 (G.N. No. S 273/2021) is amended —

- (a) by deleting the words “for any reason other than being actively infected with a COVID-19 infection or being a carrier of COVID-19” in sub-paragraph (a); and
- (b) by deleting sub-paragraph (c).

Deletion and substitution of First Schedule

3. The First Schedule to the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) Regulations 2021 is deleted and the following Schedule substituted therefor:

“FIRST SCHEDULE

Regulations 2(1) and 6(3) and (4)

VACCINATION AND APPROVED VACCINES

<i>First column</i>	<i>Second column</i>	<i>Third column</i>	<i>Fourth column</i>
<i>Approved vaccine</i>	<i>Vaccination</i>	<i>Start</i>	<i>End</i>
1. Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine)	(1) Two doses, administered at least 17 days apart.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(2) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine administered at least 17 days after the firstmentioned dose is administered.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(3) One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

	(4) One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID-19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of "recovered individual" in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(5) Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (1), (2), (3) and (4).	14th day after the last dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
2. Moderna COVID-19 vaccine	(1) Two doses, administered at least 24 days apart.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(2) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine administered at least 17 days after the firstmentioned dose is administered.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

	(3) One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(4) One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID-19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of “recovered individual” in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(5) Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (1), (2), (3) and (4).	14th day after the last dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
3. Covishield COVID-19 vaccine or Vaxzevria (AstraZeneca COVID-19 vaccine)	(1) Two doses, administered at least 24 days apart.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

	<p>(2) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine administered at least 17 days after the firstmentioned dose is administered.</p>	<p>14th day after the second dose is administered in accordance with the second column.</p>	<p>365th day (including that day) after the start of the period.</p>
	<p>(3) One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).</p>	<p>14th day after the dose is administered in accordance with the second column.</p>	<p>365th day (including that day) after the start of the period.</p>
	<p>(4) One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID-19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of “recovered individual” in regulation 2(1).</p>	<p>14th day after the dose is administered in accordance with the second column.</p>	<p>365th day (including that day) after the start of the period.</p>

	(5) Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (1), (2), (3) and (4).	14th day after the last dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
4. Johnson & Johnson's (J&J) Janssen COVID-19 vaccine	(1) One dose.	14th day after the dose is administered.	365th day (including that day) after the start of the period.
	(2) One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of "recovered individual" in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(3) One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID-19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of "recovered individual" in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

	(4) Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (2) and (3).	14th day after the last dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
5. Sinopharm COVID-19 vaccine	(1) Two doses, administered at least 17 days apart.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(2) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine administered at least 17 days after the firstmentioned dose is administered.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(3) One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

	(4) One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID-19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of "recovered individual" in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(5) Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (1), (2), (3) and (4).	14th day after the last dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
6. Sinovac-Coronavac COVID-19 vaccine	(1) Two doses, administered at least 13 days apart.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(2) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine administered at least 17 days after the firstmentioned dose is administered.	14th day after the second dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

	(3) One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(4) One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID-19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of “recovered individual” in regulation 2(1).	14th day after the dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.
	(5) Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (1), (2), (3) and (4).	14th day after the last dose is administered in accordance with the second column.	365th day (including that day) after the start of the period.

[G.N. Nos. S 310/2021; S 324/2021; S 367/2021;
S 396/2021; S 513/2021; S 542/2021; S 590/2021;
S 620/2021]

Made on 7 September 2021.

NG HOW YUE
*Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.*

[AG/LEGIS/SL/137/2020/13 Vol. 1]